+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pancreatic Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5319138
  • Report
  • April 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • AB Science
  • Astra Zeneca
  • Eli Lilly and Company
  • Infinity Pharmaceeuticals
  • Merck and Company
  • PharmaCyte Biotech
Pancreatic Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global pancreatic cancer drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the pancreatic cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Pancreatic Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) By Type: Endocrine Pancreatic Cancer; Exocrine Pancreatic Cancer
2) By End User: Hospitals; Clinics; Others
3) By Drugs: Afinitor; Erlotinib; Hydrochloride Everolimus; 5-FU; Flurouracil; Gemcitanine; Abraxane

Companies Mentioned: Eli Lilly and Company; F. Hoffman LA Rouch; CLOVIS ONCOLOGY; Pfizer; Novartis AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Astra Zeneca
  • Eli Lilly and Company
  • Infinity Pharmaceeuticals
  • Merck and Company
  • PharmaCyte Biotech
1. Executive Summary

2. Pancreatic Cancer Drugs Market Characteristics

3. Pancreatic Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Pancreatic Cancer Drugs

5. Pancreatic Cancer Drugs Market Size And Growth
5.1. Global Pancreatic Cancer Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Pancreatic Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Pancreatic Cancer Drugs Market Segmentation
6.1. Global Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Endocrine Pancreatic Cancer
  • Exocrine Pancreatic Cancer
6.2. Global Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals
  • Clinics
  • Others
6.3. Global Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Afinitor
  • Erlotinib
  • Hydrochloride Everolimus
5-FU
  • Flurouracil
  • Gemcitanine
  • Abraxane
7. Pancreatic Cancer Drugs Market Regional And Country Analysis
7.1. Global Pancreatic Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Pancreatic Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Pancreatic Cancer Drugs Market
8.1. Asia-Pacific Pancreatic Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.4. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Pancreatic Cancer Drugs Market
9.1. China Pancreatic Cancer Drugs Market Overview
9.2. China Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.4. China Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Pancreatic Cancer Drugs Market
10.1. India Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.3. India Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Pancreatic Cancer Drugs Market
11.1. Japan Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.3. Japan Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Pancreatic Cancer Drugs Market
12.1. Australia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.3. Australia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Pancreatic Cancer Drugs Market
13.1. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.3. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Pancreatic Cancer Drugs Market
14.1. South Korea Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.3. South Korea Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Pancreatic Cancer Drugs Market
15.1. Western Europe Pancreatic Cancer Drugs Market Overview
15.2. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.4. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Pancreatic Cancer Drugs Market
16.1. UK Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.3. UK Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Pancreatic Cancer Drugs Market
17.1. Germany Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.3. Germany Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Pancreatic Cancer Drugs Market
18.5. France Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.6. France Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.7. France Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Pancreatic Cancer Drugs Market
19.1. Eastern Europe Pancreatic Cancer Drugs Market Overview
19.2. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.4. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Pancreatic Cancer Drugs Market
20.1. Russia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.3. Russia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Pancreatic Cancer Drugs Market
21.1. North America Pancreatic Cancer Drugs Market Overview
21.2. North America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.4. North America Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Pancreatic Cancer Drugs Market
22.1. USA Pancreatic Cancer Drugs Market Overview
22.2. USA Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.4. USA Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Pancreatic Cancer Drugs Market
23.1. South America Pancreatic Cancer Drugs Market Overview
23.2. South America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.4. South America Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Pancreatic Cancer Drugs Market
24.1. Brazil Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.3. Brazil Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Pancreatic Cancer Drugs Market
25.1. Middle East Pancreatic Cancer Drugs Market Overview
25.2. Middle East Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.4. Middle East Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Pancreatic Cancer Drugs Market
26.1. Africa Pancreatic Cancer Drugs Market Overview
26.2. Africa Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.4. Africa Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Pancreatic Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Pancreatic Cancer Drugs Market Competitive Landscape
27.2. Pancreatic Cancer Drugs Market Company Profiles
27.2.1. Eli Lilly and Company
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. F. Hoffman LA Rouch
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. CLOVIS ONCOLOGY
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Pfizer
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Novartis AG
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Pancreatic Cancer Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Pancreatic Cancer Drugs Market

30. Pancreatic Cancer Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Astra Zeneca
  • Eli Lilly and Company
  • Infinity Pharmaceeuticals
  • Merck and Company
  • PharmaCyte Biotech
Major players in the pancreatic cancer drugs market are Eli Lilly and Company, F. Hoffman LA Rouch, Clovis Oncology, Pfizer, and Novartis AG.

The global pancreatic cancer drugs market is expected to grow from $0.6 billion in 2020 to $0.61 billion in 2021 at a compound annual growth rate (CAGR) of 1.7%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.71 billion in 2025 at a CAGR of 3.9%.

The pancreatic cancer drugs market consists of sales of drugs used to treat pancreatic cancer. Pancreatic cancer is a disease caused by the unrestrained growth of cells in the pancreas, thus disrupting the production of digestive juices and hormones responsible to regulate the blood sugar level in the body. This abnormal growth of cells leads to tissue lumps referred as tumors. The presence of tumors hinders the normal pancreas functioning.

In February 2019, Eli Lilly and Company, a US-based company that develops, manufactures, and markets pharmaceutical products worldwide, acquired Loxo Oncology, Inc. for $8 billion. With this acquisition, Eli Lilly will be able to expand its portfolio into the market for precision medicines which will be able to target pancreatic cancer caused by specific gene abnormalities. Loxo Oncology, Inc., a US-based company focuses on building small molecule cancer drugs for genetically defined patient subsets.

The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drugs market. With the rise in number of pancreatic cancer cases, the demand for drugs is expected to increase as well, which will drive the growth of the market. The number of cancer cases have increased mainly due to ageing population and increase in number of people suffering from obesity. For instance, in April 2018, 75% of new cases of pancreatic cancer patients’ age is between 55-84 years old. Also, in 2018, it has been observed that, in the US the incidence of pancreatic cancer has increased by 0.5% year on year for more than a decade.

As per the regulations laid down by the Food and Drug Administration (FDA), any pancreatic drug which seeks approval by FDA has to clear three phases of clinical trial process. The drug should be proved to be safe and promising at each phase before moving on to the next one, in order to become eligible for approval from the Food and Drug Administration (FDA). The European Medicine Association has laid down guidelines for clinical development of pancreatic drugs including setting of standards for patient's diet with respect to the drug, and establishing criteria for primary efficacy of the drug during the development stage in the clinical trial process, thereby ensuring that effectiveness of the drugs on cancer cells is established while the drug is still in the development stage in clinic.

One of the major restraints of the pancreatic cancer drugs market is the inadequacy of results given by the drugs at the time of treatment. The inadequacy in the result is due to aggressive nature of the pancreatic cancer as the cancer cells break away from main tumor and enters into blood stream, spreading the cancer cells throughout the body in a short period of time therefore this cancer is usually discovered late. The late discovery of pancreatic cancer affects the efficacy of the drugs because the drugs can work effectively only if cancer is detected timely in an early stage itself (In the stage 1 or stage 2 where cancer cells are limited to where the tumor is present). Therefore, the mortality rate for pancreatic cancer is very high. For instance, in April 2019, in Japan out of the total number of people diagnosed for pancreatic cancer, only 5-10% survived.

The concept of combination therapy over monotherapy is one of the latest ongoing trend in the pancreatic cancer drugs market. Major players in the market understand that the combination of two or more drugs is a suitable way to increase the efficacy of the drugs and thus increasing the rate of survival of patients being diagnosed with pancreatic cancer. Some of the companies investing in the combination therapy are Rafael Pharmaceuticals announced initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in combination with Modified FOLFIRINOX as first line treatment for patients with Metastatic Pancreatic Cancer in December 2018 and Apexigen, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new clinical data on APX005M in combination therapy in patients with metastatic pancreatic cancer in March 2019.
Note: Product cover images may vary from those shown
  • Eli Lilly and Company
  • F. Hoffman LA Rouch
  • CLOVIS ONCOLOGY
  • Pfizer
  • Novartis AG
  • Amgen
  • Celegene Corporation
  • AB Science
  • GlaxoSmithKline
  • Abbvie Inc.
  • Medinova
  • Vital Nutrients
  • Threshhold Pharmaceeuticals
  • Teva Pharmaceuticals
  • Merck and Company
  • PharmaCyte Biotech
  • Shire
  • Astellas
  • Astra Zeneca
  • Ipsen
  • Janssen
  • Nucana
  • Eleison Pharmaceuticals
  • Infinity Pharmaceeuticals
  • Genentech
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll